777 A New Generation Polymer-Free Amphilimus Eluting Stent in Complex PCI: A Single Centre Experience

The new generation Cre8 EVO amphilimus drug eluting stent (DES) has an improved architecture and design which is favourable for complex percutaneous coronary intervention (PCI). However, there is lack of data for this new generation DES in complex lesions which our study aims to address. This physician-initiated, single centre, prospective observational study enrolled consecutive patients undergoing complex PCI with a Cre8 Evo DES. The primary endpoint was major adverse cardiac events (MACE), a composite of cardiac death, myocardial infarction or target lesion revascularisation at 30 days. From January 2019 to March 2020 100 patients with 109 complex lesions were enrolled. Mean age was 66±9 years, 65% were male, 21% diabetic, 17% current smokers, 57% presented with an acute coronary syndrome and 87% had radial access. Lesion locations were the left main (6%), left anterior descending (40%), circumflex (18%) and right coronary (36%). Treated lesion characteristics were: chronic total occlusions (19%), long lesions (74%), heavily calcified lesions (34%), aorto-ostial lesions (13%), in-stent restenosis (10%) or bifurcation lesions with a side branch >2 mm (39%). Intravascular imaging and rotational atherectomy were used in 72% and 8% respectively. Mean number of stents per lesion was 1.4±0.6mm, mean stent diameter was 3.18±0.5mm and mean stent length was 40±21mm. Angiographic success was 100%. At 30 days MACE was 3% (Three periprocedural myocardial infarctions). We found the Cre8 Evo stent to be highly deliverable with good short-term outcomes in complex lesions. One year outcomes are awaited.